OPPM
Opus Point Partners Management Portfolio holdings
AUM
$46.9M
This Quarter Return
+4.63%
1 Year Return
-4.17%
3 Year Return
+83.22%
5 Year Return
+175.29%
10 Year Return
–
AUM
$104M
AUM Growth
+$104M
(-3.4%)
Cap. Flow
-$5.88M
Cap. Flow
% of AUM
-5.68%
Top 10 Holdings %
Top 10 Hldgs %
55.77%
Holding
60
New
9
Increased
3
Reduced
31
Closed
17
Top Buys
| 1 |
iShares Russell 2000 ETF
IWM
|
$23M |
| 2 |
iShares Biotechnology ETF
IBB
|
$4.55M |
| 3 |
SPDR S&P Biotech ETF
XBI
|
$3.18M |
| 4 |
GSK
GSK
|
$2.17M |
| 5 |
IQVIA
IQV
|
$1.41M |
Top Sells
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
$3.3M |
| 2 |
ProShares Ultra NASDAQ Biotechnology
BIB
|
$2.64M |
| 3 |
EPZM
Epizyme, Inc
EPZM
|
$2.3M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$1.88M |
| 5 |
Pacira BioSciences
PCRX
|
$1.86M |
Sector Composition
| 1 | Healthcare | 62.03% |
| 2 | Real Estate | 0.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
iShares Russell 2000 ETF
IWM
$67B
| $23M | 22.21% | +200,000 | New | +$23M |
|
2
Bristol-Myers Squibb
BMY
$96B
| $5.27M | 5.09% | 71,703 -5,397 | -7% | -$397K |
|
3
Merck
MRK
$210B
| $4.82M | 4.66% | 83,700 -6,300 | -7% | -$363K |
|
|
4
iShares Biotechnology ETF
IBB
$5.6B
| $4.55M | 4.39% | +17,681 | New | +$4.55M |
|
5
Pfizer
PFE
$141B
| $3.95M | 3.82% | 112,300 +2,300 | +2% | +$81K |
|
6
Alkermes
ALKS
$4.78B
| $3.58M | 3.46% | 82,858 -19,419 | -19% | -$839K |
|
7
AstraZeneca
AZN
$248B
| $3.28M | 3.17% | 108,563 +29,463 | +37% | +$890K |
|
|
8
SPDR S&P Biotech ETF
XBI
$5.07B
| $3.18M | 3.07% | +58,857 | New | +$3.18M |
|
|
MDVN
9
DELISTED
MEDIVATION, INC.
MDVN
| $3.11M | 3% | 51,561 -54,797 | -52% | -$3.3M |
|
|
SGEN
10
DELISTED
Seagen Inc. Common Stock
SGEN
| $2.99M | 2.89% | 74,093 -35,829 | -33% | -$1.45M |
|
11
Amgen
AMGN
$155B
| $2.83M | 2.74% | 18,619 -8,565 | -32% | -$1.3M |
|
12
Incyte
INCY
$16.5B
| $2.82M | 2.72% | 35,237 -16,440 | -32% | -$1.31M |
|
13
Illumina
ILMN
$15.8B
| $2.63M | 2.54% | 18,741 -2,988 | -14% | -$419K |
|
14
Mettler-Toledo International
MTD
$26.8B
| $2.62M | 2.53% | 7,188 -2,312 | -24% | -$844K |
|
15
Vertex Pharmaceuticals
VRTX
$100B
| $2.6M | 2.51% | 30,248 -10,889 | -26% | -$937K |
|
16
Nektar Therapeutics
NKTR
$568M
| $2.54M | 2.45% | 178,531 -109,627 | -38% | -$1.56M |
|
17
Regeneron Pharmaceuticals
REGN
$61.5B
| $2.53M | 2.44% | 7,233 -1,696 | -19% | -$592K |
|
|
18
Alnylam Pharmaceuticals
ALNY
$58.5B
| $2.42M | 2.34% | 43,684 -33,909 | -44% | -$1.88M |
|
|
QGENF
19
DELISTED
QIAGEN NV
QGENF
| $2.31M | 2.23% | 105,751 -29,249 | -22% | -$638K |
|
|
CELG
20
DELISTED
Celgene Corp
CELG
| $2.26M | 2.18% | 22,932 -16,664 | -42% | -$1.64M |
|
21
BioMarin Pharmaceuticals
BMRN
$11.2B
| $2.25M | 2.17% | 28,915 -19,345 | -40% | -$1.51M |
|
22
Biogen
BIIB
$19.4B
| $2.19M | 2.11% | 9,042 -2,083 | -19% | -$504K |
|
|
23
GSK
GSK
$79.9B
| $2.17M | 2.09% | +50,000 | New | +$2.17M |
|
|
ALXN
24
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $2.02M | 1.95% | 17,301 -8,104 | -32% | -$946K |
|
25
Agios Pharmaceuticals
AGIO
$2.19B
| $1.81M | 1.75% | 43,295 -7,705 | -15% | -$323K |
|